Collegium Pharmaceutical, Inc. — Earnings Quality Grade F
COLL · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 99 days, change -33 days YoY
AR growth -7.5% vs revenue growth 23.6%
Revenue 23.6%, CFFO 60.7%. Cash follows revenue
Expense Quality
Inventory 15.1% vs COGS 24.9%. Normal
CapEx growth 5.3% vs revenue 23.6%. Normal
SG&A/Gross Profit = 61.5%. Normal
Gross margin 59.3%, change -0.4pp. Stable
Cash Flow Quality
CFFO/NI = 5.24. Profits backed by cash
FCF $0.3B, FCF/NI = 5.21
Accruals ratio = -16.1%. Low accruals
Cash $0.4B covers only 47% of debt $0.8B
Balance Sheet Health
Goodwill+Intangibles $0.8B = 270% of equity. Over 50%
Debt/EBITDA = 2.0x. Healthy
Other assets grew 125.7% vs revenue 23.6%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -23% YoY. Normal
Manipulation Score
M-Score = -3.33 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor COLL continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25